The European Patent Office published EP3594233A1, a patent application by Merus B.V. for methods and means of producing Ig-like molecules (antibodies and fragments). The publication covers IPC classifications C07K 16/12, C07K 16/26, C07K 16/36, and C07K 16/46, designating all EU member states, Switzerland, Norway, and other European states as covered jurisdictions.

This is a routine patent publication notice. Compliance officers for pharmaceutical and biotechnology companies should review the patent claims to assess potential freedom-to-operate implications for any overlapping Ig-like molecule development programs. No immediate action is required; however, legal counsel should be engaged if any ongoing research programs may fall within the scope of the disclosed claims.